🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14,283 results for “B” Clear

  1. DOXORUBICIN, Pralatrexate, PREDNISONE, Belinostat, VINCRISTINE SULFATE, CYCLOPHOSPHAMIDE

    Lacuna Pharma Pty Ltd

    Peripheral T-Cell Lymphoma

    phase 3 small molecule active

    1 trial

  2. DOXYCYCLINE SANDOZ 100 mg, comprimé sécable, EXTENCILLINE 2,4 MUI, poudre et solvant pour suspension injectable IM

    Pari Pharma GmbH

    early syphilis

    phase 3 small molecule active

    1 trial

  3. DR-1011

    Teva Pharma GmbH

    Contraception

    phase 3 small molecule completed

    1 trial

  4. DR-102

    Teva Pharma GmbH

    Contraception

    phase 3 small molecule completed

    1 trial

  5. DR-1021

    Teva Pharma GmbH

    Healthy

    phase 3 small molecule completed

    1 trial

  6. DR-1021

    Teva Pharma GmbH

    Contraception

    phase 3 small molecule completed

    1 trial

  7. DR-103

    Teva Pharma GmbH

    Pregnancy Prevention

    phase 3 small molecule completed

    1 trial

  8. DR-104

    Teva Pharma GmbH

    Emergency Contraception

    phase 3 small molecule completed

    1 trial

  9. DR-2011

    Teva Pharma GmbH

    Infertility

    phase 3 small molecule completed

    2 trials

  10. DR-2041a

    Teva Pharma GmbH

    Menopause

    phase 3 small molecule completed

    1 trial

  11. DR-3001

    Teva Pharma GmbH

    Overactive Bladder

    phase 3 small molecule completed

    1 trial

  12. DR-5001

    Teva Pharma GmbH

    Respiratory Tract Diseases

    phase 3 mab completed

    1 trial

  13. DS-8201a

    Daiichi Sankyo

    Advanced (unresectable or metastatic) human epidermal growth receptor 2 (HER2)-expressing/HER2-mutated solid tumors

    phase 3 small molecule active

    1 trial

  14. DS-8201a, Kadcyla 100 mg powder for concentrate for solution for infusion.

    Daiichi Sankyo

    Metastatic breast cancer

    phase 3 small molecule active

    1 trial

  15. DS-8201a, Kadcyla 100 mg powder for concentrate for solution for infusion., Kadcyla 160 mg powder for concentrate for solution for infusion.

    Daiichi Sankyo

    High-Risk HER2-Positive Breast Cancer

    phase 3 small molecule active

    1 trial

  16. DTG + 3TC

    ViiV Healthcare B.V.

    HIV Infections

    phase 3 small molecule completed

    1 trial

  17. DTaP-HB-PRP~T combined vaccine

    Sanofi Pasteur

    Diphtheria

    phase 3 mab completed

    1 trial

  18. DTaP-HB-PRP~T vaccine

    Sanofi Pasteur

    Diphtheria

    phase 3 mab completed

    1 trial

  19. DULAGLUTIDE , Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide

    Eli Lilly Co.

    Type 2 Diabetes Mellitus

    phase 3 small molecule active

    1 trial

  20. DUOFAG, Chlorid sodný B. Braun 0,9 % infuzní roztok

    Lacuna Pharma Pty Ltd

    Complicated skin wounds (wounds healing per secundam via granulation tissue) - either as a complication of healing of acute wounds (infected surgical or traumatic wounds) or chronic wounds, in both cases infected with S. aureus and/or P. aeruginosa.

    phase 3 small molecule active

    1 trial

  21. DURVALUMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN, ETOPOSIDE, Olaparib, CARBOPLATIN, MK-7339, Olaparib Placebo, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, PEMETREXED, PACLITAXEL

    Merck Sharp and Dohme

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  22. DURVALUMAB, MYCOPHENOLIC ACID , Padcev 20 mg powder for concentrate for solution for infusion, TREMELIMUMAB, Padcev 30 mg powder for concentrate for solution for infusion, INFLIXIMAB

    AstraZeneca AB

    Bladder Cancer

    phase 3 small molecule active

    1 trial

  23. DURVALUMAB, Savolitinib, MYCOPHENOLATE MOFETIL, Sutent 12.5 mg hard capsules, Sutent 25 mg hard capsules, Sutent 12.5 mg hard capsules, INFLIXIMAB, Sutent 25 mg hard capsules

    AstraZeneca AB

    MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  24. DVS SR

    Wyeth is now a wholly owned subsidiary of Pfizer

    Depressive Disorder, Major

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources